Seal Rock Therapeutics, Inc.
Seattle, WA
- UEI
- P23WBJRKFLA1
- CAGE
- 8SVE5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 600 Stewart St Ste 400, Seattle, WA 98101, USA
- Website
- sealrocktx.com
- Founded
- 2016
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Targeting ASK1 as a novel therapy to treat biliary atresia - abstract text the objective of this sttr proposal is to… | National Institute of Diabetes and Digestive and Kidney Diseases | $693,820 | |
| Preclinical evaluation of ASK1 inhibitor SRT 055 as a potential development candidate for ALS | Defense Health Agency | $550,000 | |
| A novel therapy for acute alcoholic hepatitis - each year approximately 5 million people in the US develop acute… | National Institute on Alcohol Abuse and Alcoholism | $716,478 |
About Seal Rock Therapeutics, Inc.
Seal Rock Therapeutics, Inc. is a for-profit corporate entity based in Seattle, Washington, specializing in developing innovative pharmaceutical therapies targeting complex liver and neurological diseases. Registered in SAM.gov since November 2020, the company focuses on developing novel kinase inhibitors, particularly ASK1 (Apoptosis Signal-regulating Kinase 1) inhibitors, to address unmet medical needs in various disease areas. Their research and development efforts are primarily centered on creating therapeutic interventions for challenging medical conditions with limited existing treatment options.
The company has secured multiple federal grant awards from prestigious agencies, including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Defense Health Agency, and National Institute on Alcohol Abuse and Alcoholism. These grants support preclinical research on their lead compound SRT-015, targeting conditions such as neonatal biliary atresia, acute alcoholic hepatitis, and potentially neurological disorders like ALS. The grants, ranging from approximately $346,910 to support specific research projects, have enabled Seal Rock Therapeutics to conduct extensive studies exploring the therapeutic potential of ASK1 inhibition. Their research involves developing and testing SRT-015 in various animal models, with objectives including establishing optimal dosing, evaluating efficacy in treating inflammatory and fibrotic liver conditions, and investigating potential applications in neurological disease management. The company's grant-funded work demonstrates a comprehensive approach to developing innovative pharmaceutical interventions through rigorous scientific research and preclinical testing.
Quick answers
What is Seal Rock Therapeutics, Inc.'s UEI?
Seal Rock Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is P23WBJRKFLA1.
What is Seal Rock Therapeutics, Inc.'s CAGE code?
Seal Rock Therapeutics, Inc.'s CAGE code is 8SVE5.
What is Seal Rock Therapeutics, Inc.'s primary NAICS code?
Seal Rock Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Seal Rock Therapeutics, Inc. located?
Seal Rock Therapeutics, Inc.'s physical address in SAM.gov is 600 Stewart St Ste 400, Seattle, WA 98101, USA.
Is Seal Rock Therapeutics, Inc. registered in SAM.gov?
Yes. Seal Rock Therapeutics, Inc.'s SAM.gov registration is active through July 1, 2027.
What is Seal Rock Therapeutics, Inc.'s most recent federal award?
Seal Rock Therapeutics, Inc.'s most recent federal grant award is Targeting ASK1 as a novel therapy to treat biliary atresia - abstract text the objective of this sttr proposal is to… (R41DK143902), from National Institute of Diabetes and Digestive and Kidney Diseases, on September 15, 2025.
On GovTribe
See Seal Rock Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors